Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug

Reuters01-05 22:30

Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug

Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug (CHS-114), in the December 2025 issue of Molecular Cancer Therapeutics. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619309-en) on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601887628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601887628","market":"fut","top_or_hot":-1,"title":"Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug (CHS-114), in the December 2025 issue of Molecular Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619309-en) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug (CHS-114), in the December 2025 issue of Molecular Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619309-en) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL66XKlM:1","article_id":"2601887628","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601887628","pubTimestamp":1767623415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug , in the December 2025 issue of Molecular Cancer Therapeutics. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4535":"淡马锡持仓","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CHRS":"Coherus Biosciences","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"Coherus Oncology宣布在研CCR8抗体Tagmokitug临床前和早期临床结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CHRS":0.9},"content_text":"Coherus Oncology Announces Positive Preclinical and Early Clinical Results for Investigational CCR8 Antibody Tagmokitug\n    \n\n        Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug (CHS-114), in the December 2025 issue of Molecular Cancer Therapeutics. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619309-en) on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601887628","isCrawlerRequest":true}